An interview with Prof. Piotr Galecki, national consultant in psychiatry.
How does the availability of esketamine in the drug program position Poland against European standards?
Esketamine in intranasal form, for the indication of drug-resistant depression, is already available in several European Union countries, but we must boast that Poland is at the forefront of the countries in which a drug program or drug is reimbursed. We are very happy about this, because it was usually the case that in Poland modern molecules used in psychiatry were available, but they were usually expensive for quite a long time, and reimbursement only took place when we were already one of the last countries ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
